Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SNX281 |
Synonyms | |
Therapy Description |
SNX281 acts as an agonist to stimulator of interferon genes (STING, TMEM173), which activates the immune system by stimulating cells in the tumor microenvironment, potentially resulting in a cytotoxic T-lymphocyte response against tumor cells (NCI Drug dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SNX281 | SNX-281|SNX 281 | STING1 Agonist 19 | SNX281 acts as an agonist to stimulator of interferon genes (STING, TMEM173), which activates the immune system by stimulating cells in the tumor microenvironment, potentially resulting in a cytotoxic T-lymphocyte response against tumor cells (NCI Drug dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Terminated | USA | 0 |